Description
Livagen is a synthetic tetrapeptide bioregulator with the sequence Lys-Glu-Asp-Ala (KEDA), developed by Professor Vladimir Khavinson from liver tissue polypeptide extracts. It belongs to the same Khavinson specialty research peptide class as Epithalon and Cardiogen, operating through the same intranuclear DNA-binding mechanism — but with a distinct tissue target profile spanning lymphocytes, hepatocytes, and gastrointestinal tissue. Its primary research interest centers on chromatin decondensation: Livagen is studied for its capacity to induce deheterochromatinization of densely packed chromatin, particularly ribosomal gene regions, restoring transcriptional access to genes that become silenced through heterochromatin formation in aged cell populations.
Key Characteristics
- Chromatin decondensation in lymphocytes is the most characterized research finding — published data documents activation of ribosomal genes and loosening of densely packed heterochromatin fibrils in leukocytes from subjects aged 75–88, providing one of the few examples in the Khavinson series where the intranuclear mechanism has been observed in human cell populations rather than only preclinical models
- Hepatoprotective effects in aged hepatocyte cultures are a distinct research angle specific to Livagen — preclinical data documents restoration of protein synthesis rates in aged rat hepatocytes at nanomolar concentrations, connecting this compound to liver biology research independently of its lymphocyte chromatin effects
- Shares the chromatin remodeling mechanism with Epithalon — both induce deheterochromatinization through intranuclear peptide-DNA interaction — but Epithalon’s primary research focus is telomerase activation in somatic cells, while Livagen’s is ribosomal gene activation in immune and liver cell populations, reflecting different downstream consequences of the same epigenetic mechanism
- Neutrophil phagocytic activity modulation has been documented in both healthy subjects and viral hepatitis models in laboratory conditions, extending Livagen’s immune research relevance beyond lymphocyte chromatin biology into innate immune cell function
- Evidence base is preclinical and concentrated within the Khavinson research network; the 75–88 age group lymphocyte study represents an exception where human cell data is available, though no randomized controlled clinical trials have been conducted
Handling and Storage
Store as lyophilized powder under refrigeration, away from heat, moisture, and light. As a tetrapeptide, Livagen is susceptible to proteolytic degradation under suboptimal storage conditions. Reconstitute immediately before use and avoid repeated freeze-thaw cycles.
FAQs
What is Livagen?
Livagen (KEDA) is a synthetic tetrapeptide bioregulator from the Khavinson series, derived from liver tissue polypeptide extracts. It is studied for chromatin decondensation in lymphocytes and hepatocytes — specifically deheterochromatinization of ribosomal gene regions — and for hepatoprotective effects in aged hepatocyte models. Published data includes human lymphocyte data from elderly subjects, which is unusual within the Khavinson bioregulator series.
How does Livagen differ from Epithalon in chromatin research?
Both compounds induce chromatin decondensation through the Khavinson intranuclear peptide-DNA interaction mechanism, and both have been studied in the same lymphocyte aging context. The downstream research applications diverge: Epithalon’s primary focus is telomerase activation and telomere elongation in somatic cells, while Livagen’s primary focus is ribosomal gene reactivation in immune and liver cell populations. Researchers use them to probe different functional consequences of chromatin decondensation within the same mechanistic framework.
What makes Livagen’s hepatoprotection angle distinct within the Khavinson series?
Most Khavinson bioregulators are characterized primarily through their target cell population — cardiac (Cardiogen), cartilage (Cartalax), cerebral cortex (Cortagen). Livagen is unusual in having substantive preclinical data across two distinct cell populations: lymphocytes and hepatocytes. The liver-focused data, including protein synthesis restoration in aged hepatocyte cultures, gives it a research profile that spans immune and hepatic biology.
